SCHEMBL1203223

SCHEMBL1203223

CCOC(=O)c1cccc(NC(=O)c2cnc3ccc(N4Cc5ccc(OC)cc5C4)nn23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 9/20 0.45
▸ TP53 P04637 6/20 0.45
▸ LMNA P02545 4/20 0.45
▸ TSHR P16473 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ RXFP1 Q9HBX9 3/20 0.45
▸ POLB P06746 2/20 0.45
▸ TDP1 Q9NUW8 1/20 0.44
▸ RAB9A P51151 5/20 0.44
▸ NPC1 O15118 4/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ HPGD P15428 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ ABCB1 P08183 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ P2RY12 Q9H244 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203562 0.89 MAPT (0.41) KMT2AMAPTTP53LMNATSHR
SCHEMBL1203652 0.84 MEN1 (0.43) KMT2AMAPTLMNAMAPK1RXFP1
SCHEMBL1203565 0.84 DYRK3 (0.36) MAPTTP53LMNAHSD17B10HPGD
SCHEMBL1203710 0.82 CLK1 (0.43) KMT2AMAPTLMNATDP1HPGD
SCHEMBL1202443 0.81 KMT2A (0.49) KMT2AMAPTTP53LMNATSHR
SCHEMBL1203076 0.79 PIM1 (0.51) KMT2AMAPTTP53LMNATSHR
SCHEMBL1203271 0.78 KMT2A (0.48) KMT2AMAPTTP53LMNATSHR
SCHEMBL2900291 0.77 TIPARP (0.41) MAPTHSD17B10RXFP1TDP1SMN1; SMN2
SCHEMBL1202941 0.75 KMT2A (0.47) KMT2AMAPTTP53LMNATSHR
SCHEMBL1203002 0.74 PTPN11 (0.44) MAPTTP53RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 KMT2A 1247/4885MAPT 3988/4885TP53 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback